000 | 01883 a2200529 4500 | ||
---|---|---|---|
005 | 20250517161843.0 | ||
264 | 0 | _c20171031 | |
008 | 201710s 0 0 eng d | ||
022 | _a1538-7445 | ||
024 | 7 |
_a10.1158/0008-5472.CAN-16-3565 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aRicher, Amanda L | |
245 | 0 | 0 |
_aWEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer. _h[electronic resource] |
260 |
_bCancer research _c09 2017 |
||
300 |
_a4663-4672 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAMP-Activated Protein Kinases |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
650 | 0 | 4 |
_aCell Cycle Checkpoints _xdrug effects |
650 | 0 | 4 |
_aCell Cycle Proteins _xantagonists & inhibitors |
650 | 0 | 4 |
_aCell Survival _xdrug effects |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Transgenic |
650 | 0 | 4 |
_aMutation _xgenetics |
650 | 0 | 4 |
_aNuclear Proteins _xantagonists & inhibitors |
650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xdeficiency |
650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
650 | 0 | 4 |
_aProto-Oncogene Proteins p21(ras) _xgenetics |
650 | 0 | 4 |
_aPyrazoles _xpharmacology |
650 | 0 | 4 |
_aPyrimidines _xpharmacology |
650 | 0 | 4 | _aPyrimidinones |
650 | 0 | 4 | _aTumor Cells, Cultured |
700 | 1 | _aCala, Jacqueline M | |
700 | 1 | _aO'Brien, Kelley | |
700 | 1 | _aCarson, Vashti M | |
700 | 1 | _aInge, Landon J | |
700 | 1 | _aWhitsett, Timothy G | |
773 | 0 |
_tCancer research _gvol. 77 _gno. 17 _gp. 4663-4672 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/0008-5472.CAN-16-3565 _zAvailable from publisher's website |
999 |
_c27314088 _d27314088 |